Early-Stage Breast Cancer: Multidisciplinary Collaboration in Genomic Testing

Dr. Allison DiPasquale and Dr. Sonya Reid discuss how multidisciplinary collaboration supports the integration of genomic testing into the management of early-stage HR-positive, HER2-negative breast cancer. Dr. Reid explains that close coordination among surgical, medical, and radiation oncologists helps ensure consistent communication and facilitates individualized treatment planning based on genomic assay results and clinicopathologic features. She describes how genomic information contributes to multidisciplinary tumor board discussions, particularly in complex clinical scenarios where additional pathologic findings may influence decisions regarding axillary management and adjuvant therapy. Dr. DiPasquale emphasizes that contemporary breast cancer care is increasingly collaborative, with specialists working together throughout the patient's treatment journey rather than making decisions in isolation. Both faculty highlight that integrating genomic testing within a multidisciplinary framework promotes evidence-based, patient-centered care by aligning treatment recommendations across specialties and tailoring management strategies to the biology of each patient's early-stage breast cancer.